SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR
Kind Code:
A1
Abstract not available for EP1465619
Abstract of corresponding document: WO03063859
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators SERMs alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.
Abstract of corresponding document: WO03063859
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators (SERMs) alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators SERMs alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. In particular this invention relates to the pharmaceutical use of chroman derivatives in combination with moretindrone for the treatment or prevention of osteoarthritis or rheumatoid arthritis.
Inventors:
Christiansen, Claus (DK)
Christgau, Stephan (DK)
Christgau, Stephan (DK)
Application Number:
EP20030702427
Publication Date:
10/13/2004
Filing Date:
01/13/2003
View Patent Images:
Export Citation:
Assignee:
Nordic, Bioscience AS. (DK)
International Classes:
C07D405/00; C07D405/12; A61K31/138; A61K31/138; A61K31/352; A61K31/353; A61K31/366; A61K31/37; A61K31/40; A61K31/40; A61K31/4523; A61K31/4535; A61K31/567; A61K31/567; A61K31/568; A61K31/568; A61K31/57; A61K31/57; A61K31/573; A61P3/00; A61P3/04; A61P5/00; A61P5/00; A61P9/00; A61P9/00; A61P13/00; A61P13/02; A61P15/00; A61P15/00; A61P17/00; A61P17/14; A61P19/00; A61P19/02; A61P19/10; A61P25/00; A61P25/00; A61P27/00; A61P27/12; A61P29/00; A61P29/00; A61P35/00; A61P35/00; C07J5/00; C07J5/00; C07J7/00; C07J7/00; (IPC1-7): A61K31/353; A61K31/138; A61K31/37; A61K31/4535; A61P19/02; A61P19/10
European Classes:
A61K31/138; A61K31/138+M; A61K31/353; A61K31/353+M; A61K31/37; A61K31/37+M; A61K31/4535; A61K31/4535+M; A61K31/57+M
Other References:
See references of WO 03063859A1